Form 4: Sutro Biopharma CFO Buys 19,750 Shares

Sutro Biopharma's CFO, Gregory K. Chow, purchased 19,750 shares of common stock at a weighted average price of $0.81 per share.

Summary

• Gregory K. Chow, the Chief Financial Officer (CFO) of Sutro Biopharma, Inc. (STRO), acquired 19,750 shares of the company's common stock.
• The transaction occurred on October 15, 2025.
• The shares were purchased at a weighted average price of $0.81 per share, with prices ranging from $0.8099 to $0.8100.
• Following this transaction, Gregory K. Chow directly beneficially owns 19,750 shares of Sutro Biopharma common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is positive due to an insider purchase, which typically indicates management's confidence in the company's future performance and valuation. A score of 7 reflects a moderately strong positive signal, as it's a direct investment by a key executive.

Positives

• The CFO's purchase of company stock signals confidence in the company's future prospects and valuation.
• Insider buying can be viewed positively by investors, suggesting management believes the stock is undervalued or expects positive developments.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider purchase by a key executive in a biopharma company could be interpreted as a positive signal within the sector, indicating internal confidence despite broader market or industry-specific challenges. However, a single transaction does not provide sufficient data for a comprehensive industry trend analysis.

Stakeholder Impact

• Shareholders: The purchase by the CFO may instill greater confidence among existing shareholders and potentially attract new investors, viewing it as a positive endorsement of the company's prospects.
• Employees: May boost morale and confidence among employees, seeing management's direct investment in the company's future.

Key Dates

Recommendation

The CFO's purchase of 19,750 shares at $0.81 signals management's confidence in Sutro Biopharma's future. While insider buying is generally a positive indicator, a single transaction of this size, without additional context on the company's financial performance or strategic developments, is typically not a strong enough signal for a 'buy' recommendation from a seasoned investor. It reinforces a 'hold' position for existing investors and suggests potential for future positive developments, warranting continued monitoring.

Keywords

Sutro Biopharma, STRO, Insider Trading, Form 4, Stock Purchase, CFO, Gregory K. Chow, Biopharma